0000000000750207

AUTHOR

M. Nechaeva

showing 3 related works from this author

The Joint SLR (Optical Range) and Radar-VLBI Satellite Observations using VIRAC Radio Telescope RT32, RT16 and SLR Station Riga

2020

Abstract Joint VLBI and SLR satellite tracking is a novel tracking approach to explore potential applications and to work out common procedures to coordinate observations between astronomical observatories in Latvia. Global Navigation Satellite System (GNSS) satellites equipped with laser retroreflectors have been chosen as test targets because they are accessible by both measuring techniques – satellite laser ranging (SLR) and Very Long Base Interferometry (VLBI). The first Joint SLR and VLBI observations of selected GNSS satellites using three of Latvian large-scale astronomical utilities – VIRAC radio telescopes RT32 and RT16 (Ventspils International Radio Astronomy Centre of Ventspils U…

PhysicsQC1-999General EngineeringGeneral Physics and Astronomylaw.inventionvlbiRadio telescopejoint observationslawgnss satellitesslrVery-long-baseline interferometryRange (statistics)SatelliteRadarJoint (geology)GeologyRemote sensingLatvian Journal of Physics and Technical Sciences
researchProduct

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabin…

2016

Oncologymedicine.medical_specialtybiologybusiness.industryCancerHematologyGastroesophageal Junctionmedicine.diseaseOxaliplatinCapecitabine03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinebiology.proteinmedicine030212 general & internal medicineAntibodyClaudinbusinessIMAB362Epirubicinmedicine.drugAnnals of Oncology
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct